Sumitomo Pharma begins patient treatment for Parkinson's disease
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Sumitomo Pharma began patient treatments for its regenerative medicine, Amchepry, at Kyoto University Hospital in early October. The treatment, which involves transplanting nerve cells derived from induced pluripotent stem cells, was for Parkinson's disease. The patient, a woman in her 50s, has reportedly recovered well and resumed working.
From newsonjapan.com
Why it matters
Amchepry received conditional approval from Japan's Ministry of Health, Labor and Welfare in March 2026. This first patient case marks a significant step toward making regenerative medicine available for Parkinson's disease, a condition affecting an estimated 250,000 people in Japan.
From newsonjapan.com
Who's involved
- Sumitomo PharmaJapanese multinational pharmaceutical company developing the regenerative medicine treatment
- Toru KimuraPresident of Sumitomo Pharma
- Kyoto University HospitalHospital where the first patient treatment was administered
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Sumitomo PharmaSpeculative
The clinical success milestone could validate Sumitomo Pharma's core regenerative medicine pipeline, potentially affecting future investment and contracts.
- Kyoto University HospitalSpeculative
Kyoto University Hospital may boost its clinical reputation, potentially increasing its ability to secure future research funding.
Keep exploring
The entities involved
-
Sumitomo Pharma
Japanese multinational pharmaceutical company
Nothing else this week.